



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/582,964	07/06/2000	KEITH B HOFFMAN	THUR-001	4643

7590

06/18/2002

BOZICEVIC FIELD & FRANCIS
200 MIDDLEFIELD ROAD
SUITE 200
MENLO PARK, CA 94025

EXAMINER

TRAVERS, RUSSELL S

ART UNIT

PAPER NUMBER

1617

DATE MAILED: 06/18/2002

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

Newly submitted claims 26-42 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: originally presented claims were directed to inhibiting various cell adhesion molecule cleavage in brain tissue thereby treating various pantologies. Claims 26-42, herein presented, are directed to treating a host suffering from a condition characterized by an undesirable increase in synaptic responsiveness.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 26-42 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

The amendment filed on March 12, 2002 canceling all claims drawn to the elected invention and presenting only claims drawn to a non-elected invention is non-responsive (MPEP § 821.03). The remaining claims are not readable on the elected invention because originally presented claims were directed to inhibiting various cell adhesion molecule cleavage in brain tissue thereby treating various pantologies. Claims 26-42, herein presented, are directed to treating a host suffering from a condition characterized by an undesirable increase in synaptic responsiveness.

Since the above-mentioned amendment appears to be a *bona fide* attempt to reply, applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY (30) DAYS, whichever is longer, from the mailing date of this notice within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD UNDER 37 CFR 1.136(a) ARE AVAILABLE.

RUSSELL TRAWERS
PRIMARY EXAMINER
GROUP 1200